Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.

The GOLD International COPD Conference will cover underdiagnosis, exacerbations, mucus, biologics, and a preview of the 2027 GOLD Report.

People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.

Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.